Obesity Treatments and Market Dynamics

This report outlines the current landscape of obesity treatments, particularly focusing on GLP-1 based medications such as Wegovy, Ozempic, and Mounjaro, which are significantly impacting obesity care. With over 42% of U.S. adults affected by obesity, the demand for these new medications is rapidly increasing, leading to a projected global obesity market of $75 billion by 2028. The report discusses the effectiveness of these drugs, which can achieve 15%-20% weight loss, and highlights the challenges of supply shortages and limited insurance coverage. It also addresses the potential implications of these treatments on healthcare models and the economic considerations for insurers. The report includes expert insights on the benefits and limitations of GLP-1 medications, including their side effects and the ongoing debates about their long-term viability and affordability. Furthermore, it examines the robust pipeline of new obesity treatments currently in development, indicating a growing interest in this therapeutic area.